Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
作者信息
Shehadeh Naim, Raz Itamar, Nakhleh Afif
机构信息
Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, HaAliya HaShniya Street 8, 3109601, Haifa, Israel.
Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel.
出版信息
Cardiovasc Diabetol. 2018 Aug 22;17(1):117. doi: 10.1186/s12933-018-0760-6.
Abstract
摘要
相似文献
1
Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.心血管益处备受关注：将2型糖尿病治疗模式转向对明显心血管疾病患者进行早期联合治疗。
Cardiovasc Diabetol. 2018 Aug 22;17(1):117. doi: 10.1186/s12933-018-0760-6.
2
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives.SGLT2抑制剂或GLP-1受体激动剂作为2型糖尿病的二线治疗：患者选择及前景
Vasc Health Risk Manag. 2016 Jun 4;12:239-49. doi: 10.2147/VHRM.S83088. eCollection 2016.
3
New anti-diabetic agents: major advances with unanswered questions.新型抗糖尿病药物：重大进展与未解决的问题。
Rev Cardiovasc Med. 2020 Dec 30;21(4):489-492. doi: 10.31083/j.rcm.2020.04.220.
4
Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.新型降糖药物与二甲双胍联合治疗 2 型糖尿病的心血管疗效的性别差异。
J Am Heart Assoc. 2020 Jan 7;9(1):e012940. doi: 10.1161/JAHA.119.012940. Epub 2020 Jan 4.
5
Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.在最近的心血管结局试验中评估的降糖治疗的真实世界应用和建模影响：NCDR® 研究到实践项目。
Eur J Prev Cardiol. 2017 Oct;24(15):1637-1645. doi: 10.1177/2047487317729252. Epub 2017 Sep 5.
6
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.18 项心血管结局试验中血糖控制的改善和主要心血管事件的减少：更新的荟萃回归分析。
Cardiovasc Diabetol. 2021 Oct 18;20(1):210. doi: 10.1186/s12933-021-01401-8.
7
Lowering Blood Pressure with the Combination of a Sodium-Glucose Cotransporter 2 Inhibitor and a Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetic Patients: A Clinical Evidence.钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂联合用于2型糖尿病患者降压治疗：临床证据
High Blood Press Cardiovasc Prev. 2018 Dec;25(4):417-420. doi: 10.1007/s40292-018-0280-1. Epub 2018 Sep 24.
8
New Therapeutic Strategies for Type 2 Diabetes .2型糖尿病的新治疗策略
Methodist Debakey Cardiovasc J. 2018 Oct-Dec;14(4):281-288. doi: 10.14797/mdcj-14-4-281.
9
Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?使用抗高血糖药物治疗心力衰竭：现在是合适的时机吗？
Circulation. 2019 May 21;139(21):2383-2385. doi: 10.1161/CIRCULATIONAHA.119.038854.
10
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.二甲双胍治疗的 2 型糖尿病中伴有中度心血管风险患者的附加治疗：一项全国性研究。
Cardiovasc Diabetol. 2020 Jul 6;19(1):107. doi: 10.1186/s12933-020-01078-5.
引用本文的文献
1
Prescribing Antidiabetic Medications Among GPs in Croatia-A Real-Life Cross-Sectional Study.克罗地亚全科医生开具抗糖尿病药物的真实横断面研究
Biomedicines. 2025 Jun 17;13(6):1491. doi: 10.3390/biomedicines13061491.
2
The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation.CHA2DS2-VASc评分对药物洗脱支架植入患者支架内再狭窄的预测价值
Int J Gen Med. 2023 Jan 5;16:69-76. doi: 10.2147/IJGM.S391312. eCollection 2023.
3
Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.二甲双胍- SGLT2i 与二甲双胍-磺酰脲类药物在 2 型糖尿病中的心血管安全性和疗效：系统评价和随机对照试验的荟萃分析。
Sci Rep. 2021 Jan 8;11(1):137. doi: 10.1038/s41598-020-80603-8.
4
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.全球范围内，在伴有高风险因素的 2 型糖尿病患者中使用心脏肾脏保护型降糖药物（SGLT2i 和 GLP-1 RA）的情况并不积极。
Cardiovasc Diabetol. 2020 Oct 23;19(1):185. doi: 10.1186/s12933-020-01154-w.
5
Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.二甲双胍对冠心病患者全因和心血管死亡率的影响：系统评价和更新的荟萃分析。
Cardiovasc Diabetol. 2019 Jul 30;18(1):96. doi: 10.1186/s12933-019-0900-7.
6
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.在 SUSTAIN 6 试验中，每周一次司美格鲁肽可降低 2 型糖尿病患者的心血管风险：基于性别、年龄和基线心血管风险特征的事后分析。
Cardiovasc Diabetol. 2019 Jun 6;18(1):73. doi: 10.1186/s12933-019-0871-8.
本文引用的文献
1
Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.2 型糖尿病的心血管结局研究：SGLT2 抑制剂与 GLP-1 受体激动剂的比较。
Diabetes Res Clin Pract. 2018 Sep;143:88-100. doi: 10.1016/j.diabres.2018.06.008. Epub 2018 Jun 23.
2
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults.成人2型糖尿病的药物血糖管理
Can J Diabetes. 2018 Apr;42 Suppl 1:S88-S103. doi: 10.1016/j.jcjd.2017.10.034.
3
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.美国临床内分泌医师协会和美国内分泌学会关于2型糖尿病综合管理算法的共识声明 - 2018执行摘要
Endocr Pract. 2018 Jan;24(1):91-120. doi: 10.4158/CS-2017-0153. Epub 2018 Jan 17.
4
Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care.2型糖尿病患者心血管疾病的患病率及医疗护理标准评估：一项全国性初级医疗研究
Cardiovasc Endocrinol. 2017 Dec;6(4):145-151. doi: 10.1097/XCE.0000000000000135. Epub 2017 Oct 31.
5
8. Pharmacologic Approaches to Glycemic Treatment: .8. 血糖治疗的药物治疗方法： 。
Diabetes Care. 2018 Jan;41(Suppl 1):S73-S85. doi: 10.2337/dc18-S008.
6
Liraglutide and Renal Outcomes in Type 2 Diabetes.利拉鲁肽与 2 型糖尿病患者的肾脏结局。
N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.
7
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
8
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.钠-葡萄糖协同转运蛋白2抑制剂：糖尿病肾病联合治疗的新选择。
Cardiovasc Diabetol. 2017 May 16;16(1):65. doi: 10.1186/s12933-017-0547-1.
9
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
10
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
Zotero 插件